4 MONTH BIOMED GRANT LETTER WAS SENT TO D DEERFIELD

一种常见的非甾体抗炎药，布洛芬，是作为外消旋混合物销售。 这是 然而，光学活性异构体更有商业价值 特别是制药行业。 在过去几 多年来，研究人员已经能够分离对映体， 使用L-赖氨酸作为拆分剂的传统结晶技术 剂 这个过程虽然成功，但很耗时，因为它 取决于晶体的形成。 使用超临界流体 提供了一种快速和廉价的解决方案的潜在手段。 我们 开发了一种适用于超临界碳的拆分剂 二氧化物介质。 通过初步的分子模拟研究， 作为阿林格MM 3力场的增强形式， 对布洛芬的对映体具有足够的选择性， 理论基础 我们合成并表征了 拆分剂，其为氟化L-赖氨酸衍生物。 我们 布洛芬对映体的尝试和理论展望 超临界二氧化碳中的分离将与 手性氨基酸系统在非传统介质中的有效性。

A common NSAID, ibuprofen, is marketed as a racemic mixture. It's optically active isomer however, is more commercially valuable particularly to the pharmaceutical industry. Within the past few years investigators have been able to separate the enantiomers by traditional crystallization techniques using L-lysine as a resolving agent. This process, though successful, is time consuming because it is dependent upon crystal formation. The use of supercritical fluids affords a potential means to quick and inexpensive resolution. We have developed a resolving agent suitable for a supercrititcal carbon dioxide medium. Through preliminary molecular modeling studies using a augmented form of Allinger's MM3 force field, this agent appears sufficiently selective for the enantiomers of ibuprofen on a theoretical basis. We have synthesized and characterized our resolving agent, which is a fluorinated L-lysine derivative. Our attempts and theoretical expectations of enantiomeri ibuprofen separations in supercritical carbon dioxide will be related to the effectiveness of chiral amino acid systems in non-traditional media.